Skip to Main Content

Blog Posts

Blog Post
Feb. 14, 2018

Wistar Science Highlights: Funding for Malaria Research, Wistar Scientist Appointed Head of International Society for Vaccines, Potential New Therapy for Epithelial Ovarian Cancer

In the past month, Wistar has received funding that will allow the Vaccine & Immunotherapy Center and its collaborators to develop a DNA-based vaccine against malaria. Additionally, David B. Weiner, Ph.D., has been appointed president of the International Society for Vaccines, and a new study has shown how a class of drugs currently in clinical development could be used to treat epithelial ovarian cancer.

Blog Post
Feb. 6, 2018

RNA: More Than Just a Messenger

RNA biology is a central area of research at Wistar, where scientists are working to further our understanding of the functions of RNA and their relevance to cancer, infections and other types of diseases.

While most people know about DNA and its function as the material that carries our genetic information, fewer people are familiar with its distant cousin RNA. However, RNA has been known since the late 1800s, and research on its function has been recognized with some 30 Nobel Prizes over the years.

Blog Post
Jan. 12, 2018

Wistar Science Highlights: New Findings on Ovarian Cancer, Anticancer DNA Vaccine, Immunosuppressive Myeloid Cells in Infants

Three Wistar studies published in the past month shed light on a variety of topics, including the physiological role of myeloid derived suppressor cells (MDSCs) in the earliest stages of life, an anticancer DNA vaccine targeting the tumor microenvironment and a novel combination therapy that was shown to be effective in the treatment of ovarian cancer.